IWILFIN (Eflornithine) Tablets

IWILFIN (eflornithine), from US WorldMeds, is indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.

Eflornithine is an irreversible inhibitor of ornithine decarboxylase (ODC), an enzyme involved in polyamine synthesis that is often overactive in neuroblastoma driven by MYCN gene amplification. By blocking ODC, eflornithine reduces polyamine levels that support neuroblastoma cell growth, helping to lower the risk of disease relapse after initial successful treatment.

• Hearing loss (ototoxicity) has been reported; audiometric monitoring is recommended before and during treatment.
• Bone marrow suppression can occur; blood counts should be monitored periodically.
• Gastrointestinal effects such as diarrhea are common and may require supportive management.
• Common side effects: otitis media, diarrhea, upper respiratory tract infection.

What documents are required to import IWILFIN to India?

IWILFIN may be imported in the patient’s name only, by patients or government hospitals. The following documentation is required:

• A valid prescription from a registered pediatric oncologist
• Diagnostic report confirming high-risk neuroblastoma and prior treatment response
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription and an import permit, if applicable.

Is IWILFIN available in India?

IWILFIN is not commercially marketed in India. It can be legally accessed through the Named Patient Program (NPP).

Indian Pharma Network (IPN) can source IWILFIN from US WorldMeds’ authorized distribution network and facilitate supply to patients, doctors, and hospitals under applicable legal provisions.

For IWILFIN cost in India and availability, contact IPN at Phone: +91-9310090915 or email info@indianpharmanetwork.in.

Global Approval Status:

• United States: Approved by the FDA — December 2023.

What is IWILFIN used for?

IWILFIN reduces the risk of relapse in high-risk neuroblastoma patients who responded to prior multiagent therapy including anti-GD2 immunotherapy.

Who manufactures IWILFIN?

IWILFIN is manufactured by US WorldMeds.

What monitoring does IWILFIN require?

Regular hearing tests (audiometry) and blood count monitoring are recommended during treatment.

How much does IWILFIN cost in India?

Cost depends on monthly quantity and sourcing logistics — share your prescription with IPN for a quote.